FluoSphera is a Swiss biotech developing scalable and transferable human-relevant 3D tissue technologies to improve drug efficacy and safety prediction while reducing reliance on animal testing.
Our proprietary platform combines Pleiad, a portfolio of ready-to-use 3D human tissues, with color-coded multi-tissue systems that recreate complex human biology in a practical, standardized format. Designed for automation and high-content analysis, the platform can be transferred and deployed across laboratories.
FluoSphera is building a portfolio of differentiated applications across efficacy, safety, DMPK-Tox and biomarker discovery. The company has established recurring pharmaceutical customers and signed its first evaluation license agreement with a global CRO, validating the transferability of the platform and its licensing potential. We are scaling through a hybrid business model combining product sales, specialized assays and technology licensing, supported by CRO and distribution partnerships.
We are launching our Series A to accelerate platform automation and transfer, expand the Pleiad product and assay portfolio, grow our international partner network and advance our first human-relevant assay toward regulatory qualification.
